To degrade or inhibit, that’s the question

The battle over AR antagonists and degraders rages on as new clinical data emerge

February 23, 2022

Pulling a rabbit out of a hat

Surprises galore in the unveiling of the PARP data in 1L mCRPC!

February 21, 2022

Sotorasib impresses unexpectedly in pancreatic cancer

Trick or treat? A look at the sotorasib data in PDAC.

February 14, 2022

Olaparib drives earlier and deeper responses in mCRPC

An important phase 3 readout to mull over - what's not to like?

February 14, 2022

A case to answer

Will the eganelisib data be positive in TNBC from the MARIO-3 trial?

February 17, 2021

New developments in Genitourinary cancers

Highlights from ASCO GU 2020 with some interesting targets and emerging molecules to consider

February 17, 2020

ASCO GU19 Renal Cancer Review

What's hot in renal cancers? We take a look at what to expect at ASCO GU19 and offer insights on the emerging data

February 15, 2019

A look at what’s new in GU malignancies

What can we learn from the key trials being presented at ASCO GU19 in San Francisco?

February 14, 2019

New developments in Prostate Cancer

A review of key abstracts in prostate cancer expected at ASCO GU19 in San Francisco

February 13, 2019

How will the RCC landscape change – who dares, wins?!

A look at the changing face of the RCC landscape, including current and near term trial readouts

February 13, 2018

The death of PD-L1 in urothelial cancer

As inconsistent data abounds, is it time to move on from PD-L1 as a biomarker of response to checkpoint blockade?

February 12, 2018

Future directions in advanced prostate cancer

A look at some new targeted and IO combinations in development for advanced prostate cancer

February 9, 2018

Apalutamide is not a winner at ASCO GU

Will apalutamide and enzalutamide make headway in the M0 prostate cancer setting?

February 8, 2018

GU18 Preview – Promise and Pitfalls Abound

Highlights and Lowlights from ASCO GU 2018 - what to watch out for.

February 5, 2018

Go Forth and PROSPER

Interview with Dr Daniel George on Phase 3 PROSPER trial results

February 5, 2018

Why didn’t Ipilimumab plus Chemo work in Metastatic Urothelial Cancer?

A trial of gemcitabine plus cisplatin plus ipilimumab in patients with metastatic urothelial cancer failed to meet it's primary endpoint.

January 22, 2016

Potential of a Novel Non-Invasive Liquid Biopsy Prostate Cancer Biomarker

A novel non-invasive liquid biopsy may offer a potential novel biomarker that will help in sequencing prostate cancer drugs.

January 21, 2016

New combinations and targets in advanced prostate cancer

How do we overcome resistance to Zytiga? There are some encouraging developments in this area to report.

January 20, 2016

A New Race to Market in Advanced Prostate Cancer

Two biotech companies are in a race to market for a novel target in advanced prostate cancer.

January 19, 2016

How to make non-immunogenic cancers sensitive to checkpoint inhibitors

Not all cancers respond to checkpoint inhibitors - how can we change that situation? Here's one example, using prostate cancer as a model...

March 2, 2015

Is AR-V7 a useful predictive biomarker in advanced prostate cancer

The ongoing story of the AR-V7 splice variant as a potential biomarker of response in mCRPC

February 23, 2015

Enzalutamide beats bicalutamide in advanced prostate cancer

The Phase 2 TERRAIN trial met its primary endpoint (PFS) with enzalutamide beating out bicalutamide in castrate resistant prostate cancer. What next?

January 22, 2015

ASCO GU 2015 Preview

What's hot at ASCU GU 2015? Focus on prostate and bladder cancers with checkpoint inhibitors and sequencing therapies

February 26, 2015

ASCO GU 2014: Will there be a market for Medivation’s enzalutamide in M0 prostate cancer?

The new race to market in advanced prostate cancer is in the M0 asymptomatic space. Several AR antagonists are competing to run trials here but will they lead to men living longer or not?

February 10, 2014

Update on immuno-oncology and biomarkers of response

ASCO GU saw an update on the ipilimumab study in post chemotherapy CRPC. New biomarker data published this week in melanoma may be potentially useful in prostate and other tumour types.

February 5, 2014

ASCO GU 2014 Optimal targeting of anti PD-1 and PD-L1 therapies in renal cancer

Update on progress with anti-PD1 and PD-L1 immunotherapies in renal cell cancer. Where is the field going in this space?

February 4, 2014

ASCO GU 2014 Beyond Enzalutamide and Abiraterone – What’s Next?

Cross resistance between enzalutamide and abiraterone means that new prostate cancer drugs and targets are needed.

January 31, 2014

ASCO GU 2014: Will Galeterone make it to market in Prostate Cancer?

At ASCO GU 2014 Tokai Pharmaceuticals report data for the ARMOR2 trial with reformulated galeterone (TOK-001) in men with prostate cancer. Is this drug likely to make it to market?

January 30, 2014

ASCO GU Interview with Dr Tom Beer on Medivation PREVAIL trial data

Enzalutamide significantly decreases the risk of death and delays progression in the PREVAIL trial

January 28, 2014

ASCO GU 2014: Why does the Medivation PREVAIL trial matter?

At ASCO GU this week, the clinical data will be presented for the Medivation/Astellas PREVAIL phase III clinical trial of enzalutamide (Xtandi) in men with advanced prostate cancer prior to chemotherapy. The results of this trial not only have important commercial implications for Medivation/Astellas but for competitors in the prostate cancer market.

January 27, 2014

Will Exelixis Cabozantinib COMET-1 prostate cancer trial be positive?

The share price of Exelixis ($EXEL) is starting a run-up (after months in the doldrums) in advance of anticipated results from the COMET-1 phase 3 trial in metastatic castrate resistant prostate cancer (mCRPC) for cabozantinib (Cometriq, formerly XL184). Cabozantinib has been shown to significantly improve bone scans and decrease pain, but will it show an improvement in OS?

January 6, 2014

ASCO GU 2014 Prostate Cancer Preview #GU14

ASCO GU symposium takes place at the San Francisco Marriott Marquis from Jan 20 – February 1, 2014. This preview discusses data to be presented on enzalutamide (Xtandi), abiraterone (Zytiga), ODM-201, ARN-509, ipilimumab (Yervoy).

December 30, 2013